What one share of BioRegenx holds
Findit, Inc. resulting in a change of control. Pursuant to the terms of the merger, the name of the company was changed to BioRegenx,
BioRegenx’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-03-31; the balance sheet is as of 2026-03-31.
| Sales | $0.00 |
|---|---|
| Profit | −$0.00 |
| Cash and investments | $0.00 |
| Debt | $0.00 |
| Book value | −$0.00 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $0.00 | −$0.00 | — | — | — | −$0.00 |
| 2022 | $0.00 | −$0.00 | — | — | — | −$0.01 |
| 2023 | $0.01 | −$0.01 | $0.00 | −$0.00 | — | −$0.00 |
| 2024 | $0.00 | −$0.03 | $0.00 | −$0.00 | — | −$0.00 |
| 2025 | $0.00 | −$0.00 | $0.00 | $0.00 | — | −$0.00 |
Common questions about BioRegenx
How much does one share of BioRegenx earn?
Over the last 12 months, BioRegenx lost $0.00 for each share on $0.00 of sales.
Does BioRegenx pay a dividend?
BioRegenx didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is BioRegenx’s book value per share?
BioRegenx’s book value is negative (−$0.00 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of March 31, 2026.
How much cash and debt does each share of BioRegenx have?
Each share of BioRegenx has $0.00 of cash and investments and $0.00 of debt, as of March 31, 2026.
Has BioRegenx bought back shares?
BioRegenx’s share count rose about 256% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.